News
»
Vivacelle Bio, Inc. Announces FDA Clearance to Enroll Patients into a Phase IIa Clinical Trial of VBI-S for Elevation of Blood Pressure in Subjects Who Have Shock Due to Sepsis
Vivacelle Bio, Inc. Announces FDA Clearance to Enroll Patients into a Phase IIa Clinical Trial of VBI-S for Elevation of Blood Pressure in Subjects Who Have Shock Due to Sepsis
Vivacelle Bio, Inc. announces that the US Food and Drug Administration (FDA) has granted Dr. Cuthbert Simpkins, MD its Founder and Chief Innovation Officer, an Investigational New Drug (IND) clearance to proceed with a phase IIa clinical trial of the safety and efficacy of VBI-S. Vivacelle Bio, Inc. provided support for the investigational new drug application to the U.S. Food & Drug Administration for a phase IIa clinical trial of VBI-S.
Latest News
(BPRW) Tech Visionary and Trailblazing Innovator Edwige A. Robinson to Address Graduates at DeVry University’s Commencements
(BPRW) Powerful Free Health Equity Summit to Take Place in Washington, DC, Hosted by The Greater Washington Community Foundatio
(BPRW) Kappa Alpha Psi Fraternity, Inc. announces new $2 million fundraising commitment for St. Jude Children’s Research Hospital
(BPRW) The Congressional Black Caucus Foundation Partners with Paramount Pictures on the Release of the new “Bob Marley: One Love” Film to Provide Social Justice Scholarships